Insomnia Market Overview:
Global Insomnia Market was valued at $4,093 million in 2016, and is estimated to reach $5,488 million by 2023, registering a CAGR of 4.2% from 2017 to 2023. Insomnia is a sleep disorder where in the person faces difficultly to sleep or remain asleep. The symptoms include low stamina, daytime sleepiness, depression, and irritability. It is a highly prevalent disorder that affects millions of people, worldwide. Insomnia-related conditions are caused due to disruption in circadian rhythm, chronic pain, hyperthyroidism, menopause, psychological stress, and other medical conditions. Moreover, excessive use of drugs, such as caffeine, alcohol, and nicotine could lead to insomnia. This disorder can be diagnosed in sleep laboratories using various diagnostic devices. Depending on the duration of the disorder, insomnia is divided into three types, namely transient, acute, and chronic insomnia. In transient insomnia, the symptoms persist from a few days to a few weeks; acute insomnia persists for several weeks; and chronic insomnia last for months to a few years.
Global Insomnia Market Segmentation
The global insomnia market is segmented based on therapy type and geography. Based on therapy type, it is bifurcated into non-pharmacological and pharmacological therapy. Non-pharmacological therapy is further categorized into hypnotherapy, cognitive behavioral therapy, medical devices, and other non-pharmacological therapy. Pharmacological therapy is further divided into prescription sleep aids and over-the-counter sleep aids. Based on region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Drivers, Restraints, and Opportunities
The impact of the driving factors is expected to surpass the effect of restraints. Moreover, technological advancements have led to higher adoption rate and untapped markets in the developing economies are expected to provide new avenues for the growth of the insomnia market in the near future.
Drivers and Restraints
Global Insomnia Market: Key Geographical Segments
North America accounted for the highest market share in the insomnia market in 2016, and is expected to maintain its dominance throughout the forecast period.
Global Insomnia Market, by Region, 2016 (%)
The key players operating in the global insomnia market include Merck & Co. Inc., Sanofi, Pfizer, Inc., Takeda Pharmaceutical Company Ltd., Purdue Pharmaceuticals L.P., Eisai, Co. Ltd., Meda Consumer Healthcare Inc., Pernix Therapeutics, Vanda Pharmaceuticals, and ECR Pharmaceuticals.
The other prominent players in the value chain include Fidia Farmaceutici, Dainippon Sumitomo, Biocodex, Eli Lilly and Company, and Ebb Therapeutics.
- This report entails a detailed quantitative analysis of the current market trends from 2016 to 2023 to identify the prevailing opportunities.
- Market estimations are based on comprehensive analysis of the key developments in the industry.
- The global market is comprehensively analyzed with respect to therapy type and geography.
- In-depth analysis based on geography assists in understanding the regional market to assist in strategic business planning.
- The growth strategies adopted by key manufacturers assist in understanding the competitive scenario of the market.
Insomnia Market Key Segments:
By Therapy Type
- Non-pharmacological Therapy
- Cognitive Behavioral Therapy
- Medical Devices
- Other Non-pharmacological Therapy
- Pharmacological Therapy
- Prescription Sleep Aids
- Over-the-counter Sleep Aids
- North America
- Rest of Europe
- Rest of Asia-Pacific
- Republic of South Africa
- Saudi Arabia
- Rest of LAMEA